文献速递前列腺癌

泛癌分析揭示CDK12改变定义一类具有独特基因组与临床特征的前列腺癌亚型

Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
PubMed 文献 · Eur Urol · 2020-04-19

该单中心回顾性研究对25种实体瘤共26743例患者进行肿瘤测序,发现CDK12改变总体频率为1.5%,但在前列腺癌(5.3%)和卵巢癌(4.2%)中最常见。CDK12改变的前列腺癌具有独特的拷贝数变异谱和致癌通路改变,临床特征更具侵袭性,总生存期更短,且独立于标准临床因素和肿瘤拷贝数负荷。

要点

  • CDK12改变在泛癌中罕见(1.5%),但前列腺癌中频率最高(5.3%)。
  • CDK12改变的前列腺癌具有独特拷贝数变异谱和细胞周期通路基因改变。
  • CDK12改变与更短总生存期独立相关(调整HR 1.80)。

核心结论

  • CDK12改变是泛癌中的罕见事件,但定义了一个临床独特的分子亚型前列腺癌,与独特基因组改变和略更具侵袭性的临床特征相关。

研究设计与样本

  • 单中心回顾性研究,纳入25种实体瘤类型共26743例接受肿瘤测序的患者,评估前列腺癌的临床病理特征和结局。

主要发现

  • CDK12改变总体见于404/26743例患者(1.5%),在前列腺癌(100/1875,5.3%)和卵巢癌(43/1034,4.2%)中最常见,且与截短变异和双等位基因失活的高 prevalence 相关。
  • CDK12改变定义的前列腺癌基因组亚型具有独特的拷贝数变异谱和涉及不同致癌通路(包括细胞周期通路基因)的改变。
  • CDK12改变的前列腺癌与略更具侵袭性的临床特征和更短总生存期相关(中位64.4 vs 74.9个月;p=0.032),独立于标准临床因素和肿瘤拷贝数改变负荷(调整风险比1.80,95%置信区间1.12-2.89;p=0.024)。

临床怎么用

  • 对前列腺癌患者进行CDK12改变检测可能有助于识别具有独特基因组特征和略差预后的分子亚型,为潜在靶向治疗研究提供依据。

局限性

  • 研究为回顾性性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CDK12 genomic alterations occur in several tumor types, but little is known about their oncogenic role and clinical significance. OBJECTIVE: To describe the landscape of CDK12 alterations across solid cancers and the clinical features of CDK12-altered prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: A single-center retrospective study of 26743 patients across 25 solid tumor types who underwent tumor sequencing was performed. Clinicopathologic features and outcomes were assessed in prostate cancer. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: CDK12 alterations and their association with genomic characteristics are described. For prostate cancer patients, overall survival and time to castration resistance were assessed using univariable and multivariable Cox regression analysis. RESULTS AND LIMITATIONS: CDK12 alterations were identified in 404/26743 patients (1.5%) overall, but were most frequent in prostate (100/1875, 5.3%) and ovarian cancer (43/1034, 4.2%), in which they were associated with a high prevalence of truncating variants and biallelic inactivation. CDK12 alterations defined a genomic subtype of prostate cancer with a unique copy-number alteration profile and involvement of distinct oncogenic pathway alterations, including cell-cycle pathway genes. CDK12-altered prostate cancer was associated with somewhat more aggressive clinical features and shorter overall survival (median 64.4 vs 74.9 mo; p=0.032) independent of standard clinical factors and tumor copy-number alteration burden (adjusted hazard ratio 1.80, 95% confidence interval 1.12-2.89; p=0.024). The study is limited by its retrospective nature. CONCLUSIONS: CDK12 alteration is a rare event across solid cancers but defines a clinically distinct molecular subtype of prostate cancer associated with unique genomic alterations and slightly more aggressive clinical features. PATIENT SUMMARY: CDK12 gene alterations occur rarely across tumor types, but more frequently in prostate cancer, where they are associated with genomic instability, cell-cycle pathway gene alterations, and somewhat worse clinical outcomes, warranting further investigation of therapeutic targeting of this disease subset.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nguyen B, Mota JM, Nandakumar S, et al. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. Eur Urol. 2020. PMID: 32317181. doi:10.1016/j.eururo.2020.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。